keyword
MENU ▼
Read by QxMD icon Read
search

Herceptin

keyword
https://www.readbyqxmd.com/read/29766242/inactivation-of-deubiquitinase-cyld-enhances-therapeutic-antibody-production-in-chinese-hamster-ovary-cells
#1
Yafang Lu, Qin Zhou, Qianqian Han, Pengfei Wu, Lanlan Zhang, Lin Zhu, David T Weaver, Changzhi Xu, Buchang Zhang
Chinese hamster ovary (CHO) cells are promising host engineering cells for industry manufacturing of therapeutic antibodies. However, cell death due to apoptosis remains a huge challenge to augment antibody production, and developing CHO cells with enhanced anti-apoptosis and proliferation ability is fundamental for cell line development and high-yielding bioprocesses. Deubiquitinase cylindromatosis (CYLD) has been proved to be a tumor suppressor by negatively regulating NF-κB and Wnt/β-catenin signaling pathways...
May 15, 2018: Applied Microbiology and Biotechnology
https://www.readbyqxmd.com/read/29736306/lmo4-mediates-trastuzumab-resistance-in-her2-positive-breast-cancer-cells
#2
Keshuo Ding, Zhengsheng Wu, Xiaocan Li, Youjing Sheng, Xiaonan Wang, Sheng Tan
Breast cancer is the leading cause of cancer-related mortality in women worldwide. Trastuzumab (Herceptin) is an effective antibody drug for HER2 positive breast cancer; de novo or acquired trastuzumab resistance retarded the use of trastuzumab for at least 70% of HER2 positive breast cancers. In this study, we reported LMO4 (a member of LIM-only proteins) promoted trastuzumab resistance in human breast cancer cells. Over-expression of LMO4 was observed in acquired trastuzumab resistance breast cancer cells SKBR3 HR and BT474 HR...
2018: American Journal of Cancer Research
https://www.readbyqxmd.com/read/29731915/target-specific-delivery-of-oxaliplatin-to-her2-positive-gastric-cancer-cells-in-vivo-using-oxaliplatin-au-fe3o4-herceptin-nanoparticles
#3
Daren Liu, Xiaowen Li, Changlei Chen, Chao Li, Chuanbiao Zhou, Weidong Zhang, Jiangang Zhao, Jie Fan, Kai Cheng, Li Chen
Gastric cancer is the fourth most common malignancy globally. In order to decrease the dosage and side effects of conventional chemotherapy, and achieve improved benefits from molecular targeted therapy, novel drug delivery systems were developed in the present study. Oxaliplatin-Au-Fe3 O4 -Herceptin® acts as a dual-functional nanoparticles (NPs) conjugate and possesses the capability of human epithelial growth factor receptor 2 (HER2) targeting and oxaliplatin delivery. The 8-20 nm Au-Fe3 O4 were synthesized by decomposing iron pentacarbonyl on the surfaces of Au NPs in the presence of oleic acid and oleylamine...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29671404/regulation-of-dual-specificity-phosphatases-in-breast-cancer-during-initial-treatment-with-herceptin-a-boolean-model-analysis
#4
Petronela Buiga, Ari Elson, Lydia Tabernero, Jean-Marc Schwartz
BACKGROUND: 25% of breast cancer patients suffer from aggressive HER2-positive tumours that are characterised by overexpression of the HER2 protein or by its increased tyrosine kinase activity. Herceptin is a major drug used to treat HER2 positive breast cancer. Understanding the molecular events that occur when breast cancer cells are exposed to Herceptin is therefore of significant importance. Dual specificity phosphatases (DUSPs) are central regulators of cell signalling that function downstream of HER2, but their role in the cellular response to Herceptin is mostly unknown...
April 11, 2018: BMC Systems Biology
https://www.readbyqxmd.com/read/29644518/mathematical-modelling-of-the-interaction-between-cancer-cells-and-an-oncolytic-virus-insights-into-the-effects-of-treatment-protocols
#5
Adrianne L Jenner, Chae-Ok Yun, Peter S Kim, Adelle C F Coster
Oncolytic virotherapy is an experimental cancer treatment that uses genetically engineered viruses to target and kill cancer cells. One major limitation of this treatment is that virus particles are rapidly cleared by the immune system, preventing them from arriving at the tumour site. To improve virus survival and infectivity Kim et al. (Biomaterials 32(9):2314-2326, 2011) modified virus particles with the polymer polyethylene glycol (PEG) and the monoclonal antibody herceptin. Whilst PEG modification appeared to improve plasma retention and initial infectivity, it also increased the virus particle arrival time...
April 11, 2018: Bulletin of Mathematical Biology
https://www.readbyqxmd.com/read/29626535/biophysical-properties-and-heating-induced-aggregation-of-lysine-conjugated-antibody-drug-conjugates
#6
Aditya V Gandhi, Keith J Arlotta, Hsiao-Nung Chen, Shawn C Owen, John F Carpenter
The commercially available antibody-drug conjugate (ADC) product, Kadcyla® is synthesized using a two-step reaction, wherein the linker is conjugated to native lysines on the monoclonal antibody (mAb) in step 1, followed by drug conjugation to the linker-modified antibody in step 2. In our study, we synthesized a lysine conjugated ADC (Syn-ADC) on the same trastuzumab scaffold as Kadcyla® using a one-step reaction. Mass spectrometry of both products revealed a sub-population of Kadcyla® containing free linkers conjugated to the mAb, but not conjugated to the drug, which were absent in the one-step reaction ADC product...
April 4, 2018: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29577949/quantification-of-ligand-density-and-stoichiometry-on-the-surface-of-liposomes-using-single-molecule-fluorescence-imaging
#7
Lisa Belfiore, Lisanne M Spenkelink, Marie Ranson, Antoine M van Oijen, Kara L Vine
Despite the longstanding existence of liposome technology in drug delivery applications, there have been no ligand-directed liposome formulations approved for clinical use to date. This lack of translation is due to several factors, one of which is the absence of molecular tools available for the robust quantification of ligand density on the surface of liposomes. We report here for the first time the quantification of proteins attached to the surface of small unilamellar liposomes using single-molecule fluorescence imaging...
March 22, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29574771/monoclonal-antibody-based-therapeutics-targeting-the-epidermal-growth-factor-receptor-family-from-herceptin-to-pan-her
#8
REVIEW
Shima Moradi-Kalbolandi, Aysooda Hosseinzade, Malihe Salehi, Parnaz Merikhian, Leila Farahmand
OBJECTIVES: Monoclonal antibody-based of cancer therapy has been considered as one of the most successful therapeutic strategies for both haematologic malignancies and solid tumours in the last two decades. Epidermal growth factor receptor (EGFR) family signalling pathways play a key role in the regulation of cell proliferation, survival and differentiation. Hence, anti-EGFR family mAbs is one of the most promising approaches in cancer therapy. KEY FINDINGS: Here, recent advances in anti-EGFR mAb including approved or successfully tested in preclinical and clinical studies have been reviewed...
March 25, 2018: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/29544445/long-term-trastuzumab-herceptin%C3%A2-treatment-in-a-continuation-study-of-patients-with-her2-positive-breast-cancer-or-her2-positive-gastric-cancer
#9
Volkmar Müller, Michael Clemens, Jacek Jassem, Nedal Al-Sakaff, Petra Auclair, Eveline Nüesch, Debbie Holloway, Mona Shing, Yung-Jue Bang
BACKGROUND: Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data available on long-term H treatment of patients. The Rollover Protocol (ROP) Study was conducted to report safety data for patients with HER2-positive locally advanced/metastatic breast and gastric/GEJ cancer who have received long-term H therapy (≥ 5 years and ≥ 3 years for breast and gastric/GEJ cancer, respectively)...
March 15, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29534020/copper-free-click-chemistry-based-synthesis-and-characterization-of-carbonic-anhydrase-ix-anchored-albumin-paclitaxel-nanoparticles-for-targeting-tumor-hypoxia
#10
Katyayani Tatiparti, Samaresh Sau, Kaustubh A Gawde, Arun K Iyer
Triple negative breast cancer (TNBC) is a difficult to treat disease due to the absence of the three unique receptors estrogen, progesterone and herceptin-2 (HER-2). To improve the current therapy and overcome the resistance of TNBC, there is unmet need to develop an effective targeted therapy. In this regard, one of the logical and economical approaches is to develop a tumor hypoxia-targeting drug formulation platform for selective delivery of payload to the drug-resistant and invasive cell population of TNBC tumors...
March 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29502805/a-randomized-phase-i-study-comparing-the-pharmacokinetics-of-hd201-a-trastuzumab-biosimilar-with-european-union-sourced-herceptin
#11
Xavier Pivot, Jean Paul Deslypere, Lisa Soyeon Park, Michael Jinwoo Kim, Wonjae Lee, Jeonghyeon Lee
PURPOSE: This first-in-human study of HD201 was designed to evaluate the pharmacokinetic (PK) equivalence between this biosimilar candidate and trastuzumab sourced in the European Union (EU-trastuzumab)*. METHODS: In this randomized, blinded, single-dose comparative PK study, healthy male subjects were randomized to receive a single 6 mg/kg IV dose of HD201 or EU-trastuzumab. The primary PK end point was AUC0-∞ . Equivalence was determined by using the predefined margins of 0...
March 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29500066/a-kinetically-controlled-isothermal-method-for-the-detection-of-single-nucleotide-mismatches
#12
Yoshiaki Masaki, Devon Cayer, Ryan McBride, M Reza Ghadiri
We describe an isothermal, enzyme-free method to detect single nucleotide differences between oligonucleotides of close homology. The approach exploits kinetic differences in toe-hold-mediated, nucleic acid strand-displacement reactions to detect single nucleotide polymorphisms (SNPs) with essentially "digital" precision. The theoretical underpinning, experimental analyses, predictability, and accuracy of this new method are reported. We demonstrate detection of biologically relevant SNPs and single nucleotide differences in the let-7 family of microRNAs...
February 14, 2018: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29483955/recombinant-nanocomposites-by-the-clinical-drugs-of-abraxane-%C3%A2-and-herceptin-%C3%A2-as-sequentially-dual-targeting-therapeutics-for-breast-cancer
#13
Shuang Ding, Jian Xiong, Dan Lei, Xiao-Li Zhu, Hai-Jun Zhang
Breast cancer greatly threatens the health of women all over the word despite of several effective drugs. Targeted therapy for breast cancer is limited to human epidermal growth factor receptor 2 (HER2). Herceptin® , monoclonal antibody against HER2, is now widely used in HER2(+) breast cancer. Abraxane® , the current gold standard for paclitaxel (PTX) delivery, has shown superiority in breast cancer based on nanoparticle albumin bound technology. Despite these advances, further novel targeted therapy with more improved anti-tumor efficacy for breast cancer is still urgently needed...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29482416/evaluation-of-analytical-similarity-between-trastuzumab-biosimilar-ct-p6-and-reference-product-using-statistical-analyses
#14
Jihun Lee, Hyun Ah Kang, Jin Soo Bae, Kyu Dae Kim, Kyoung Hoon Lee, Ki Jung Lim, Min Joo Choo, Shin Jae Chang
The evaluation of analytical similarity has been a challenging issue for the biosimilar industry because the number of lots for reference and biosimilar products available at the time of development are limited, whilst measurable quality attributes of target molecule are numerous, which can lead to potential bias or false negative/positive conclusions regarding biosimilarity. Therefore, appropriate statistical analyses are highly desirable to achieve a high level of confidence in the similarity evaluation. A recent guideline for the risk-based statistical approaches recommended by the US Food and Drug Administration provides useful tools to systematically evaluate analytical similarity of biosimilar products compared with reference products...
February 26, 2018: MAbs
https://www.readbyqxmd.com/read/29463236/rapid-symptomatic-relief-of-her2-positive-gastric-cancer-leptomeningeal-carcinomatosis-with-lapatinib-trastuzumab-and-capecitabine-a-case-report
#15
Xiao-Dong Jiao, Chunming Ding, Yuan-Sheng Zang, Guanzhen Yu
BACKGROUND: Gastric cancer patients with widespread metastasis, especially meningeal metastases, have an extremely prognosis and limited therapeutic choices. CASE PRESENTATION: We reported the case of a 39-year-old male patient with HER2-positive gastric cancer with bone and meningeal metastases. He presented with multiple bone metastases and received 3 cycles of docetaxel plus S1. However, he complained with headache and imaging examinations revealed leptomeningeal carcinomatosis...
February 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29448628/functionalized-magnetic-plga-nanospheres-for-targeting-and-bioimaging-of-breast-cancer
#16
Seung-Jun Lee, Hee-Jin Kim, Yong-Min Huh, Il Won Kim, Jae Hyun Jeong, Jin-Chul Kim, Jong-Duk Kim
Superparamagnetic iron oxide nanoparticles (SPIONs) are actively used as highly sensitive imaging probes to provide contrast in MRI. In this study, we propose the use of SPIONs encapsulated with antibody-conjugated poly(lactic-co-glycolic acid) (PLGA) as a potent theragnostic agent. The SPIONs were synthesized by a chemical co-precipitation method of ferric and ferrous ions, and subsequently encapsulated with PLGA by using an emulsification-diffusion method. Herceptin was chemically conjugated to the SPION-encapsulating PLGA nanoparticles to target the human epidermal growth factor receptor 2 (Her2/neu) overexpressing breast cancers...
March 1, 2018: Journal of Nanoscience and Nanotechnology
https://www.readbyqxmd.com/read/29434968/characterization-of-circulating-tumor-cells-in-newly-diagnosed-breast-cancer
#17
Lu Xu, Songlin Jia, Hengyu Li, Yue Yu, Guoping Liu, Yanmei Wu, Xishui Liu, Chaoqian Liu, Yue Zhou, Zhenzhen Zhang, Yuan Sheng
Identification of circulating tumor cells (CTCs) by surface marker expression and ploidy analysis [immunostaining-fluorescence in situ hybridization (iFISH)] has been shown to be a highly sensitive method in the identification of certain solid cancers. In the present study, iFISH analysis was performed to identify CTCs in 184 patients with newly diagnosed non-metastatic breast cancer, and the distribution of CTC subtypes was characterized based on cytokeratin (CK) expression and ploidy status. It was revealed that CTCs of non-metastatic, aneuploid breast cancers, independent of CK expression profile, can be detected with high sensitivity (90...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434878/progesterone-impairs-herceptin-effect-on-breast-cancer-cells
#18
Kamila Kitowska, Agnieszka Kowalska, Magdalena Mieszkowska, Dominika Piasecka, Andrzej C Skladanowski, Hanna M Romanska, Rafal Sadej
Breast cancer (BCa) is the most common cancer affecting women worldwide. Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in ~20-25% of invasive ductal breast carcinomas and is associated with the more aggressive phenotype. Herceptin, a humanized antibody against HER2, is a standard therapy in HER2-overexpressing cases. Approximately one-third of patients relapse despite treatment. Therefore numerous studies have investigated the molecular mechanisms associated with Herceptin resistance...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29430233/durable-and-complete-response-to-herceptin-monotherapy-in-patients-with-metastatic-gastroesophageal-cancer
#19
Brenen P Swofford, Tomislav Dragovich
Gastroesophageal cancer is the sixth leading cause of cancer-related death worldwide. The 2 most common histologies are squamous cell carcinoma and adenocarcinoma, which has seen an increase in incidence correlating with an increase in obesity in developed countries. Gastroesophageal adenocarcinoma has a preponderance to metastasize early, making it a highly lethal cancer with a low 5-year survival rate of ∼15-25%. Therefore, for the majority of patients, treatment focuses on palliation and prolongation of survival...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29408336/long-non-coding-rna-uca1-desensitizes-breast-cancer-cells-to-trastuzumab-by-impeding-mir-18a-repression-of-yes-associated-protein-1
#20
Hua-Yu Zhu, Wen-Dong Bai, Xing-Ming Ye, An-Gang Yang, Lin-Tao Jia
Breast cancer resistance to the monoclonal erbB2/HER2 antibody trastuzumab (or herceptin) has become a significant obstacle in clinical targeted therapy of HER2-positive breast cancer. Previous research demonstrated that such drug resistance may be related to dysregulation of miRNA expression. Here, we found that knockdown of the long non-coding RNA, urothelial cancer associated 1 (UCA1), can promote the sensitivity of human breast cancer cells to trastuzumab. Mechanistically, UCA1 knockdown upregulated miR-18a and promoted miR-18a repression of Yes-associated protein 1 (YAP1)...
February 19, 2018: Biochemical and Biophysical Research Communications
keyword
keyword
34695
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"